Objectives
Identify service offerings and / or contracting that can drive differentiation and preference of BIOSIMILAR A versus the originator biologic and other biosimilars.
Scope
Methodology
Internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.
Deliverables
- Catalogue of value-added services and contracts offered by the originator biologic across market segments.
- Biosimilar defence strategies implemented by the manufacturer of the originator biologic.
- Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake.
- Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation.
- Strategic recommendations to drive differentiation of BIOSIMILAR A.
Illustrative Outputs
Impact
CBPartners developed a strategy to drive differentiation of a biosimilar through service offerings and contracting.